ImageneBio IMA 深 滬
等待開盤 10-28 09:30:00 美东时间
4.02
-0.030
-0.74%
華盛通- 最 高4.11
- 今 開4.0799
- 成交量 4137股
- 最 低 4.02
- 昨 收 4.05
- 總市值 4563.29万
- 52周最高 8.84
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 3.88
- 委 比 6.25%
- 總股本 1135.15万
- 歷史最高 451.32
- 量 比 0.27
- 振 幅 2.22%
- 歷史最低 3.88
- 每 手 1
- 風險率 1.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
HC Wainwright & Co. Initiates Coverage On ImageneBio with Buy Rating, Announces Price Target of $28
HC Wainwright & Co. analyst Arthur He initiates coverage on ImageneBio (NASDAQ:IMA) with a Buy rating and announces Price Target of $28.
08-21 18:20
ImageneBio Q2 EPS $(0.63) Beats $(1.05) Estimate
ImageneBio (NASDAQ:IMA) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(1.05) by 40 percent.
08-05 20:06
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Wedbush Reiterates Underperform on ImageneBio, Maintains $2 Price Target
Wedbush analyst Martin Fan reiterates ImageneBio (NASDAQ:IMA) with a Underperform and maintains $2 price target.
05-11 20:31
ImageneBio Q1 EPS $(0.95) Misses $(0.70) Estimate
ImageneBio (NASDAQ:IMA) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.70) by 35.71 percent.
05-08 04:44
美股夜盘 | Synergy CHC Corp.涨106.85%，Sana Biotechnology, Inc.涨23.36%
Synergy CHC Corp.涨106.85%；Sana Biotechnology, Inc.涨23.36%；GoPro, Inc. Class A涨18.73%
04-14 13:01
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 76.7% to $0.18 du...
04-13 20:05
Market-Moving News for April 13th
IMA: 41% | ImageneBio Raises $30M Via Private Institutional Placement To Fund Hair Loss And Skin Disease Treatments IDYA: 37% | IDEAYA Biosciences and Servier's Topline Data From Phase 2/3 OptimUM-02 Trial
04-13 19:21
ImageneBio Raises $30M Via Private Institutional Placement To Fund Hair Loss And Skin Disease Treatments
ImageneBio, Inc. (NASDAQ:IMA)("Imagene" or the "Company") today announced it has entered into a definitive securities purchase agreement with certain institutional investors in a private placement that is expected to
04-13 19:06
